samarth kulkarni family

Dr. Rodger Novak, M.D., co-founder and current Chief Executive Officer of CRISPR Therapeutics, is stepping down from his current role for personal reasons but will continue to serve as a member of the Company's board of directors and as an officer of its Swiss parent company, CRISPR AG. There are 4 older executives and no younger executives at CRISPR Therapeutics. My name is Raju Prasad, I am the Research Analyst at William Blair, who covers CRISPR Therapeutics. or. Dr. Kulkarni is also on the board of Black Diamond Therapeutics, Inc., Repare Therapeutics, Inc. and Centessa Pharmaceuticals Ltd. and Chief Executive Officer & Director at CRISPR Therapeutics AG and Director-Emerging Companies Section at Biotechnology Innovation Organization. So, I think it aligns capabilities well, the capital does make a difference for us as we further expand the rest of our pipeline. Be the first to rate this post. In Bengaluru, Samarth started playing for the Social Cricket Club, where he made a remarkable impression on the coaches. The durability in BCMA has been -- has not been that great compared to CD19 in some cases, for the trials where we know the data; I think it'd be -- it'll be interesting to see what the median duration of response is for the CRs or for the legend J&J program, that would set the bar. This Home measures 552 Sq-ft is on floor 3 of 4 storey building. Samarth Kulkarni's email & phone | Crispr Therapeutics's Chief So, I think it's sort of 50-50 overall, in terms of oncology versus non-oncology. Supreme Court orders 'Z+' security to industrialist Ambani's family Dr. Samarth Kulkarni | CRISPR She is a single mother of two children, a son, Samrath Bedi, and a daughter, Divya Chawla. Dr. Kulkarni, called Sam by his friends in the U.S., is a young bio-technology scientist who has been working with CRISPR since 2015. The modern day striker has to be many things to make it to the top. Expanded Access to Investigational Medicines. Neumnster, Schleswig-Holstein, Germany. How are you thinking about it now? Yes, and part of it depends on the data. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer (CBO), and then served as President and CBO before . Leadership. The most important thing you learnt was to be friends with people who cared about you, regardless of whom they were. Art & Entertainment News, Movie Reviews, Bollywood, Hollywood, OTT Our lead assets, CTX001 and hemoglobinopathies have shown remarkable data and could be potentially curative for patients suffering from sickle cell disease and beta thalassemia; we'll talk more about this program. In addition to his expertise in biotech strategy and operations, Sam has spearheaded initiatives in . This week on the For Your Innovation Podcast, we're joined by Dr. Samarth Kulkarni, Chief Executive Officer of CRISPR Therapeutics. Nov. 2022-Heute3 Monate. Please disable your ad-blocker and refresh. And now there is this notion like in re-dose, preemptively, as a consolidation dose, and that's the way to get durability because you've completely eliminated the cancer. At Centessa Pharmaceuticals, Samarth Kulkarni has 25 colleagues including Saurabh Saha (CEO & Director), Francesco De Rubertis (Chairman of the Board) At Repare Therapeutics, Samarth Kulkarni has 14 colleagues including Lloyd Segal (CEO & Director), Jerel Davis (Director) Industry Colleagues So I think you have two players now, neck-and-neck, at the front; but we believe that CTX001, especially with the capabilities that Vertex brings to the table in terms of commercialization, globally, we would have a significant advantage. The shares were sold at an average price of $54.81, for a total value of $1,370,250.00. And I talked with autologous BCMA programs which is better than some of the other programs out there today. I think ultimately, it's because that's how we can exploit the platform to the fullest extent, to bring transformative medicines for patients. CRISPR Therapeutics AG (CRSP) CEO Samarth Kulkarni on William Blair Mira got married at the age of nineteen. The estimated net worth of Samarth Kulkarni is at least $19.12 million as of February 27th, 2023. GuruFocus has detected 3 severe warning signs with CRISPR Therapeutics AG. CEO of Crispr Therapeutics Ag (30-Year Financial, Insider Trades) Samarth Kulkarni (insider trades) sold 30,000 shares of CRSP on 06/15/2021 at an average price of $126.43 a share. A. Ghalge and P. Bhattacharyya, Information Extraction from Indo Aryan Family of Natural Languages Using a Rule . We have migrated to a new commenting platform. Samarth Kulkarni Salary Infomation 2020 | ERI Economic Research Institute Samarth Kulkarni "Sam" Chief Executive Officer . While at McKinsey, he co-led the biotechnology practice and focused on topics ranging from strategy to operations and led initiatives in areas such as personalized medicine and immunotherapy. And he will assume the role effective December 1, 2017. You know, this is a question on the oncology platform and the company commercialization strategy as a whole. Drafted Notices, Replies to Notices, etc. It almost took Kulkarni and her team two years to come up with their first product. THE 10 BEST Restaurants Near Anand Resort in Nashik, Nashik District He has authored several publications in leading scientific and business journals. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer, and then was appointed to President and Chief Business Officer before becoming CEO. Save my name, email, and website in this browser for the next time I comment. Is this happening to you frequently? Yes, I mean I think the initial data clearly derisked the B2M knockout approach which was the big question going into your first data set. I think -- I do think that eventually, there is other constructs coming out where you're turbocharging with cytokines or making other edits. The company has almost 80 stores in India,and it supplies its products to 190 hotels and exports them to 120 countries. This net worth estimate does not reflect any other investments that Dr. Kulkarni may own. Learn More about Samarth Kulkarni's net worth. Those programs are all in the clinic and we will have additional data for CTX110 this year, as well as initial data for CTX120 and CTX130; 110 being targeted towards CD19, 120 being targeted towards BCMA, and 130 being targeted towards CD70. Samarth Kulkarni Inventions, Patents and Patent Applications - Justia The most recent insider tranaction occured on February, 27th when CEO Samarth Kulkarni sold 25,000 shares worth more than $1,206,250.00. Jan 2016 - Feb 20162 months. And you mentioned Vertex, and I want to kind of drill into that a little more. I think we -- our pancreas are banana shaped organ that we're -- but only a small portion of that is actually catering towards glucose homeostasis. Dr. In 2000, Mira started a company named Forest Essentials on a small scale with soaps and candles as its first products with an investment of Rs.2 lakh. Samarth Kulkarni, Chief Executive Officer of CRISPR Therapeutics Research Centre, founded by Emmanuelle Charpentier, hails from Belagavi. But I think if we do need to go there, we will; we will probe the consolidation dose regimen if we do need to do that, and we're obviously watching carefully for data from other players to see what the consolidation doses do. Samarth Kulkarni Net Worth (2023) | wallmine IN He really liked the products and asked his country head in India about them. CRISPR Therapeutics AG has a market cap of $10.49 billion; its shares were traded at around $148.410000 with and P/S ratio of 129.60. Samarth's talent in cricket was first recognised when he represented the Karnataka State Under-14 cricket team. PubHTML5 site will be inoperative during the times indicated! Shillong (Meghalaya) - Violence erupted in three Constituencies after the results of the Assembly Elections in Meghalaya were declared. Prior to joining our . Sign Up. I think this is like the medical device space, and shares are sticky because there are certain centers learned and trained themselves on a certain product, and it's not very easy to switch. The Hindu Centre for Politics and Public Policy, Supreme Court forms expert panel to probe any regulatory failure on Adani issue, China says border should be kept in proper place, calls for resuming direct flights with India, India makes renewed push for consensus at G20 Foreign Ministers meeting, Seeping saffron: On the BJP and their partners electoral gains in the northeast, Searing changes: On heatwaves predicted by the Met Office, Sun Pharma reports information security incident, Embassy Group sells 4% stake in Embassy REIT to Bain Capital, 1947: Madras Devadasis (Prevention of Dedication) Act passed, World Test Championship points table update: India drops PCT, Australia qualifies for WTC final with Indore win; qualification scenarios. CRISPR's CEO Dr. Samarth Kulkarni - Healthcare Talks 2021 - YouTube , 2+ . Yes. Russia's war on Ukraine latest: Putin casts war as battle for nation's survival, India FM Jaishankar says Soros dangerous, debate needed on democracy, Buffett's Berkshire profit falls on investments, currencies, Bill Gates buys Heineken stake, despite saying he's 'not a big beer drinker', Elon Musk recruits team to develop OpenAI rival - The Information, Hedge fund manager Chris Hohn demands Airbus drop Atos deal - letter, Elon Musk's challenge: Stay ahead of the competition, ISS urges Apple shareholders to vote for CEO Tim Cook, other execs' pay packages, Elon Musk accuses media of racism after newspapers drop 'Dilbert' cartoon, French media billionaire Niel fails with bid for TNT television frequence - Arcom, Transcript : CRISPR Therapeutics AG Presents at Citi's 2023 Virtual Oncology Leadership Summit, Feb-22-2023 01:00 PM, Transcript : CRISPR Therapeutics AG Presents at B. Riley Securities' 3rd Annual Oncology Conference, Jan-18-2023 10:30 AM, Transcript : CRISPR Therapeutics AG Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-12-2022 11:40 AM, Chief Executive Officer & Executive Director. Systems, devices, and methods for generating and sending messages are described. The West Whiteland Township man found shot dead alongside his wife and two sons on Sunday had purchased a gun two weeks before police found the family's bodies in the basement of their home, law enforcement sources said Wednesday. So I think while it's -- you know, won't be difficult for people to enroll patients because there is a lot of demand for gene editing in sickle cell and thalassemia, I think commercially, we are well positioned to take on that leadership mantle and maintain it overtime. Training and Placement Student Coordinator at SITRC. Samarth Kulkarni Net Worth The estimated Net Worth of Samarth Kulkarni is at least CRISPR Therapeutics AG stock worth over . And thanks, again, for participating. Yes, I think -- you know, ViaCyte have an allogeneic version; I mean with embryonic stem cells, except it's not edited, right. Save my name, email, and website in this browser for the next time I comment. Responsible for troubleshooting and maintaining existing Lab test stands for pumps and motors. Updated Jan 27, 2021. So any hint of a response from allogeneic CAR-Ts in solid tumors is a pretty meaningful step for mankind, I would say. We presented data there for 10 patients; 7 thalassemia and 3 sickle cell patients, and all 10 patients were symptom-free. And subsequently what we've disclosed is that we've dosed more patients in our EHA abstract, there is a greater number of patients, we have 14 patients; 10 thalassemia, 4 sickle cell patients. And I think, you know, the -- I'm glad the field is pursuing both of those options to see what's better. E/22, Jai mahalaxmi Society, Opp. Samarth has made over 30 trades of the CRISPR Therapeutics AG stock since 2017, according to the Form 4 filled with the SEC. Dr. Samarth Kulkarni has served as our Chief Executive Officer since 2017. He then moved to Bengaluru with his father, who is a Government servant, to pursue his cricketing career. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Dr. Kulkarni owns 375,988 shares of CRISPR Therapeutics stock worth more than $19,115,230 as of March 4th. And what are the relative kinetics of it, what are the relative dynamics of it in terms of tumor volume reduction and amount of doses you need, etcetera. Can you maybe just give us a quick overview of that program, how you're viewing it? View contact number for free. Mira Kulkarni owns a Glasshouse named Neemranas Glasshouse, a riverside property with 20 accommodations, which is located on the banks of the Ganges. You can imagine we do that with the liver cells, and these liver cells are small device that are inserted into your -- under your flanks, into your flanks or in your stomach, which can serve to be a biofactory for the body, they can produce any drugs you want, they can produce any factors or proteins you want. This Supreme Court Case Could Redefine Crime, YellowstoneBackers Wanted to Cash OutThen the Streaming Bubble Burst, How Countries Leading on Early Years of Child Care Get It Right, Female Execs Are Exhausted, Frustrated and Heading for the Exits, More Iranian Schoolgirls Sickened in Suspected Poisoning Wave, No Major Offer Expected on Childcare in UK Budget, Oil Investors Get $128 Billion Handout as Doubts Grow About Fossil Fuels, Climate Change Is Launching a MutantSeed Space Race, This Former Factory Is Now New Taipeis Edgiest Project, What Do You Want to See in a Covid Memorial? CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. I know we're running short on time, but I did want to just touch briefly on the ViaCyte collaboration because I think the type 1 diabetes is becoming more of a focus for the company and going into next year as given the TAM is so big. As an avid follower of Ayurveda, Mira developed a passion for creating products that maintain the inherent properties of the ingredients found in Ayurveda. While we had exciting data with one patient in thalassemia -- two patient in thalassemia, one in sickle earlier; having 10 patients worth data made a big difference. Samarth Kulkarni Net Worth & Insider Trades - benzinga.com . You know, you're seeing response rates and CR rates that are similar to autologous therapies, right. The total sale was $2.8 million. So I think, you know, do you have to exactly meet the bar to be viable as an allogeneic therapy? Dr. Kulkarni is also on the board of Black Diamond Therapeutics, Inc., Repare Therapeutics, Inc. and Centessa Pharmaceuticals Ltd. and Chief Executive Officer & Director at CRISPR Therapeutics AG and Director-Emerging Companies Section at Biotechnology . Biography of Samarth Kulkarni - The Official Board So this one will be interesting to see the durability and the persistence of the cells and get an answer to those questions. I believe that consistent performance in junior level cricket, support of my parents and encouragement of my coaches will surely help me in achieving my dreams, he said. So, I think for 120, 130, they are still early, I think these are all things that we determine as we go along, and see what the most optimal venue is, and the most optimal timing is. [2]Vogue. Sam Kulkarni, Crispr Therapeutics Inc: Profile and Biography Samarth is a leg-spinner and middle-order batsman who is currently studying in the 9th standard at Jain Heritage School in Hebbal, Bengaluru. Facebook. And so we're learning more about CAR-Ts in general, and we're also learning more about allogeneic versus autologous therapies, and the same sort of metrics and lenses that you apply to autologous may not apply to allogeneic. CRISPR Therapeutics - Wikipedia Thanks, Sam, for joining us. Learn More about insider trades at CRISPR Therapeutics. And I think the 120 CR rates are -- seem to be higher, right; I think or BCMA, in general. He then along with Gastroenterologist and Surgeon (Dr . Samarth Bedi began his career with Standard Chartered Bank in New York in 1999, and in 2001, he joined Forest Essentials as the managing director. Samarth Kulkarni - Chief Executive Officer - LinkedIn Log In. View profile badges. Post-poll violence that erupted in at least three assembly constituencies in Meghalaya left several people injured. Tejas Dhamecha, Rudra Murthy V, Samarth Bharadwaj, Karthik Sankaranarayanan and Pushpak Bhattacharyya. Dr. Samarth Kulkarni has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. And maybe compare and contrast that with CD19, which is a little different? Samarth Kulkarni - Training and Placement Student Coordinator - Sandip Lakshmikumaran and Sridharan. News Karnataka 2012 - 2023 All Rights Reserved by, Vijayapura: Samarth Kulkarni, a blooming cricketing talent. Rooms are spacious and four persons . Deadly. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer (CBO), and then served as President and CBO before being named its CEO in 2017. Director Bradley J Phd Bolzon sold 171,004 shares of CRSP stock on 12/07/2020 at the average price of $154.53. State Government would be responsible to provide security in Mumbai and within Maharashtra, while the Ministry of Home Affairs would be responsible for . Sayali Ghodekar, Pushpak Bhattacharyya, Gholamreza Haffari and Malhar Kulkarni, Cognition-aware Cognate Detection, 16th . Will His AI Plans Be Any Different? The corporate mailing address for Dr. Kulkarni and other CRISPR Therapeutics executives is BAARERSTRASSE 14, ZUG V8, CH-6300. She realised that Rishikesh could be an ideal location where she could start her business as it is an ayurvedic, wellness hub and home to hundreds of ayurvedic doctors and there are pharmacies that sell homemade soaps, oils, lotions, creams, and other products. He has served as the companys Chief Business Officer and president before being promoted as CEO. Beyond beauty, it is your inner self. And we also said that we dosed 30 patients now; so I think the program is getting more and more momentum. Sam currently serves on the Board of Directors of two precision oncology companies, Black Diamond Therapeutics and Repare Therapeutics. . Chart Data in Insider Trading History Table. I think you saw something yesterday in the news around ICANS with autologous therapies, but you may not necessarily see that with allogeneic therapies, even if you have the same potency of killing, right. She is a single mother of two children, a son, Samrath Bedi, and a daughter, Divya Chawla. It'd be interesting to kind of hear how you're going to be approaching it, you know, learning from some of the things -- some of the aspects of the first mover has had to go through? They all have pimples and you dont. Dr. Sowmya Kulkarni - Obstetrician - Book Appointment Online - Practo If we could switch gears a little bit into the oncology pipeline; obviously, you know, going to be three separate readouts for 2021 from this pipeline. And I think it may, you know, we'll see if we need to get tinker and tailor. Sam joined CRISPR in early 2015 as Chief Business Officer. Are goalscorers born or made? Additionally, Dr. Kulkarni receives a salary of $1,180,000.00 as CEO at CRISPR Therapeutics. Yes. Please. With oncology, how we play in the long run is isn't -- it's a question that we evaluate every so often. Yes. Subways Potential $10 billion Sale Draws Goldman, Bain: Sky, Guinea Sets Two-Week Deadline for Alumina Plants Projects, Bank of Canada Risks Falling Too Far Behind Fed, Scotia Says, Feds Daly Says More Rate Hikes Likely Needed to Cool Inflation, Colombia Prices Rise Less than Forecast to a Fresh 24-Year High, VW Will Build a $2 Billion Electric Truck and SUV Plant in South Carolina, Federal Grants Aim to Reconnect Communities Divided by Highways, Meta Cuts the Price of Its Quest Headset Up to 33% After Disappointing Demand, In Blacklisting Inspur, US Targets Partner Used by Intel and IBM, John Malone andCharter Directors Agree to $87.5 Million Settlement, Congo President Tells Macron Conflict in East May Delay Election, Anti-ESG Crusader Wants to Take Trumps Agenda to Next Level, Harrods Shrugs Off Recession Fears as Rich Get Richer, FT Says, Wealthy NYC Family Feuds Over $258 Million Madison Avenue Sale, Porsche, Ferrari E-Fuel Push at Heart of EU Engine Debate, Tom Sizemore, 'Saving Private Ryan' Actor, Dies at 61. ViaCyte, a regenerative medicine company long backed by CIRM, announced a partnership with CRISPR Therapeutics to increase the number of people with Type 1 Diabetes (T1D) who could benefit from their PEC-Direct therapeutic implant.. Last year, CIRM granted ViaCyte $20 million to facilitate development of PEC-Direct, a device that both . If you're going to look to build out kind of commercial infrastructure to support global launches for that or do you partner one or more of those programs? She had appropriate expe more.. Share your story. Samarth Kulkarni is the CEO of CRISPR Therapeutics AG and owns about 369,111 shares of CRISPR Therapeutics AG (CRSP) stock worth over $19 Million.Details can be seen in Samarth Kulkarni's Latest Holdings Summary section. You know, obviously with EHA coming up next week and the data update in sickle cell and beta thal; maybe provide just a little bit of context on what to expect in terms of data updates, obviously, you've provided updates in enrollment recently in trial. Samarth Kulkarni is Chairman of Casebia Therapeutics LLP. Meanwhile Samarth said his goal is to represent bigger level cricket like the Indian Premier League (IPL) & the Indian cricket team. 1 BHK Apartment for Sale in Maval, Lonavala. This well-known establishment acts as a one-stop destination servicing customers both local and from other parts of Navi Mumbai, Mumbai. CRISPR Therapeutics (NASDAQ:NASDAQ:CRSP) 4th Annual Evercore ISI HealthCONx Conference December 1, 2021 12:35 PM ETCompany ParticipantsSamarth Kulkarni - Chief Executive OfficerConference. If we need to, we'll go that route of the GSIs but at this point, we're trying to work with the original hypothesis which is that beta-2-M gives us that persistence; it won't be overwhelmed by the soluble BCMA, and -- but we still see responses. Samarth Kulkarni has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. Samarth Kulkarni. And once you're getting to approval, it's going to move -- it's going to leapfrog autologous therapies, because it's going to move much faster, it's easier to enroll patients in allogeneic therapies versus autologous therapies; imagine trying to expand your autologous cell therapy trials to community settings, just very slow, you're not going to get there. Samarth Kulkarni is the Chief Executive Officer for CRISPR Therapeutics. Reports: 3 children dead, 2 wounded in attack at Texas home, Kellyanne Conway, George Conway To Divorce After Decadeslong Marriage: Report, School punished teen girl for working out in sports bra in 100-degree Texas heat, ACLU says, U.S. court won't require FAA to make airplane seat size, spacing rules, 'Extremely dangerous': Spike in illegal crossings at Canada-Vermont border has feds sounding alarm. And then maybe after the ASH data, if you could provide any color on how physicians are looking at the data set to date? Samarths journey in cricket started with playing for the Karnataka Cricket Club in Vijayapura. All right, thanks everybody for dialing in. I think CD70 program, the CTX130 program for us could be a very important program in the long run. No. Mira has an extensive collection of sarees including her favourite Banarasi saree that her grandmother gave her. Apart from his cricketing skills, Samarth is also good in academics, balancing his time between studies and cricket. Samarths talent in cricket was first recognised when he represented the Karnataka State Under-14 cricket team. Learn More on Samarth Kulkarni's trading history. You could hear the whispers eeks, whats that! from your friends. And obviously, you touched on this a little bit, but the global manufacturing cohesion that you have, can you maybe just describe a little bit about how that -- how to view that in the context of the rest of the pivotal -- the rest of the current clinical trial, as well, as approaching the agency, just given some things that we've seen in the space recently with regards to regulatory filings with the lentivirus procedure? A dead body of an unknown individual was found; the Police investigation is underway. He has also worked for pharmaceutical and medical technology companies. Samarth Speciality Clinic, Multi-Speciality Clinic in Wakad, Pune He also serves on the Board of the Emerging Companies Section of the Biotechnology Innovation Organization (BIO). View profile. CRISPR Therapeutics' insider roster includes Bradley Bolzon (Director), Kurt Emster (Director), Tony Ho (VP), James Kasinger (General Counsel), Lawrence Klein (COO), Samarth Kulkarni (CEO), Rodger Novak (President), and Michael Tomsicek (CFO). Training and Placement Student Coordinator at Sandip Foundation. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer, and then was appointed to President and Chief . Dr. Samarth Kulkarni has served as our Chief Executive Officer since 2017. In the last year, insiders at the sold shares 9 times. In the letter, she wrote. These are all small numbers, that -- you know, maybe sufficient to get a foothold in the market because you have a more convenient approach with allogeneic therapy, a lot of patients that don't have access to autologous therapies. Yes, I think ASH last year was a very important milestone for the program. And with that, it's a pleasure to have Sam Kulkarni, the CEO of CRISPR Therapeutics with us for this fireside chats. Click for complete details on 99acres.com Learn More on CRISPR Therapeutics' active insiders. CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Mira enjoys reading cookbooks and cooking different cuisines during her leisure time. Following the completion of the sale, the chief executive officer now directly owns 375,988 shares of the company's stock, valued at $18,141,421. And most of all, I think it makes sense for patients suffering from sickle cell disease and thalassemia because this is the best chance of making sure that this program gets wide access to all these patients that need and deserve the therapy. Samarth Kulkarni | The Stem Cellar Leadership | CRISPR But I think, you know, in this market, time is an important component; I think it's going to be difficult for -- for players to get a commercial foothold, if there has been a player existing already for four or five years with very good data, right. Join Facebook to connect with Samarth Kulkarni Kulkarni and others you may know. Thanks for that. Kulkarni has four grandchildren, Shabad Shabad, Angad, Rhea, and Samaira. So did you -- interesting to think about as a -- as the leader in your particular modality, maybe thinking about your program, as well as potential competitor programs that might get advanced in the clinical trials in the future? But I think in the interim, you need to be competitive and get a foothold. Samarth Kulkarni - Chief Executive Officer - Crunchbase What should we expect in terms of updates on the 110 program? Musk Made a Mess at Twitter.

Who Is Responsible For Managing Portfolio Kanban, Queensland Transport Approved Engineers, Can A Girl Change Her Mind After Rejecting You?, Articles S